Hidalgo et al., Semin Oncol 2003
:
Phase I pharmacokinetic studies show that treatment with erlotinib HCl ( Tarceva ; Genentech Inc, South San Francisco, CA ), an orally available epidermal growth factor receptor ( HER1/EGFR ) -tyrosine kinase inhibitor , on a daily, uninterrupted schedule is feasible
Gordon et al., Int J Gynecol Cancer 2005
(Ovarian Neoplasms) :
Efficacy and safety of erlotinib HCl , an epidermal growth factor receptor ( HER1/EGFR ) tyrosine kinase inhibitor , in patients with advanced ovarian carcinoma : results from a phase II multicenter study